Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;13(6):534-542.
doi: 10.1007/s11899-018-0482-6.

Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma

Robert Havard  1 , Deborah M Stephens  2
Affiliations
Review

Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma

Robert Havard et al. Curr Hematol Malig Rep. 2018 Dec.

Abstract

Purpose of review: This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma.

Recent findings: The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1, JULIET, and TRANSCEND NHL-001 trials. Anti-CD19 CAR-T therapy is an exciting new therapy now approved and available to patients with relapsed/refractory diffuse large B cell lymphoma. Secondary to the increasing success and availability of these products, caregivers should expect to become familiar with the indications, toxicity, and limitations of these treatment options and when patients should be considered for referral.

Keywords: Axi-cel; CAR-T; CTL019; Chimeric antigen receptor; DLBCL; Liso-cel.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mol Ther. 2017 Oct 4;25(10):2245-2253 - PubMed
    1. N Engl J Med. 2011 Aug 25;365(8):725-33 - PubMed
    1. Nat Biotechnol. 2002 Jan;20(1):70-5 - PubMed
    1. Sci Transl Med. 2015 Mar 25;7(280):280ps7 - PubMed
    1. J Clin Oncol. 2015 Feb 20;33(6):540-9 - PubMed

MeSH terms

LinkOut - more resources